IDH1 and glioma: Interestingly, human readers were unable to assess IDH mutation status by mere visually assessment in a subset of 20 patients with contrast-enhancing gliomas (sensitivity 100% (95% CI 69.15% to 100.00%) and specificity 0% (95% CI 0.00% to 30.85%)).